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Background: The purpose of this study was to explore if administration of N-acetyl-cysteine (NAC) in patients with
multiple sclerosis (MS) resulted in altered cerebral blood ﬂow (CBF) based on Arterial Spin Labeling (ASL)
magnetic resonance imaging (MRI).
Methods: Twenty-three patients with mild to moderate MS, (17 relapsing remitting and 6 primary progressive)
were randomized to either NAC plus standard of care (N ¼ 11), or standard of care only (N ¼ 12). The experimental group received NAC intravenously (50 mg/kg) once per week and orally (500mg 2x/day) the other six
days. Patients in both groups were evaluated initially and after 2 months (of receiving the NAC or waitlist control)
with ASL MRI to measure CBF. Clinical symptom questionnaires were also completed at both time points.
Results: The CBF data showed signiﬁcant differences in several brain regions including the pons, midbrain, left
temporal and frontal lobe, left thalamus, right middle frontal lobe and right temporal/hippocampus (p < 0.001) in
the MS group after treatment with NAC, when compared to the control group. Self-reported scores related to
cognition and attention were also signiﬁcantly improved in the NAC group as compared to the control group.
Conclusions: The results of this study suggest that NAC administration alters resting CBF in MS patients, and this is
associated with qualitative improvements in cognition and attention. Given these ﬁndings, large scale efﬁcacy
studies will be of value to determine the potential clinical impact of NAC over the course of illness in patients with
MS, as well as the most effective dosages and differential effects across subpopulations.

1. Introduction
Multiple sclerosis (MS) is a chronic neurological disorder characterized by focal lesions of autoimmune-mediated demyelination and
inﬂammation in the CNS. The course and clinical presentation of MS is
heterogeneous, complex, and incurable. Patients may experience a range
of neurologic and cognitive impairments that manifest through acute
episodes of reversible neurological damage followed by progressive
neurodegeneration while other patients may experience a progressive
neurodegeneration from onset [1]. Although MS is an autoimmune
mediated disease, there is an association between oxidative damage and
CNS injury [2].

Oxidative stress is commonly characterized by a redox imbalance
leading to the accumulation of oxidative species and/or a depletion of
antioxidants [3]. In MS, autoimmune induced oxidative damage contributes to a variety of biological disturbances including the disruption of
the blood brain barrier, the loss of oligodendrocytes, and mitochondrial
dysfunction in neurons [4, 5]. These disruptions play a prominent role in
the pathophysiology of MS. The brain is particularly vulnerable to
oxidative stress due to its low antioxidant content, such as glutathione,
and its high rate of metabolic activity [6]. Glutathione (GSH) is implicated in reducing oxidative radicals through glutathione peroxidase
while also governing the gene expression of inﬂammatory pathways [3,
7]. The role of oxidative stress is further substantiated by the depletion of

* Corresponding author.
E-mail address: Andrew.newberg@jefferson.edu (A.B. Newberg).
https://doi.org/10.1016/j.heliyon.2021.e07615
Received 18 January 2021; Received in revised form 23 February 2021; Accepted 14 July 2021
2405-8440/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

S. Shahrampour et al.

Heliyon 7 (2021) e07615

CBF within the brain [34]. It has been shown to be effective in detecting
decreased perfusion in grey matter [15, 16, 17] and MS severity-related
brain perfusion changes elicited by a psychological stress task [35].
Moreover, there has been additional data published showing a correlation between decreased perfusion and more severe functional disability
[36, 37]. As ASL represents a non-invasive neuroimaging modality for
quantifying CBF, it may be highly useful for the clinical evaluation of MS
patients, as well as to follow them through various interventions
designed to improve brain function and reduce the impact of the MS.
Thus, our goal is to investigate changes in CBF in MS patients before and
after receiving NAC.

glutathione stores as seen in both mouse models and MS patient MRI
scans [4, 8, 9]. Therefore, we are investigating interventions aimed at
restoring the redox imbalance seen in MS in order to mitigate the effects
of chronic oxidative stress in the CNS. These interventions, if effective,
may improve brain function and restore neuronal function [10].
It is also known that there is neurovascular coupling that helps to
ensure that functioning neurons receive sufﬁcient blood ﬂow to maintain
their need for oxygen and glucose [11]. Evidence suggests that this
coupling is preserved in MS patients [12]. However, in a variety of
neurological disorders, there is a decrease in cerebral blood ﬂow mediated either directly by the disease process affecting the microvasculature
or secondary to neuronal dysfunction [13]. Similarly, MS has been shown
to have decreased perfusion to certain areas of the brain [14, 15, 16, 17]
which is the result of neuronal dysfunction. Such dysfunction is the result
of oxidative injury in cortical neurons or retrograde neurodegeneration
due to axonal injury from demyelination in the white matter [18].
Compensatory functional adaptations might also account for MS-related
changes in brain perfusion and activity [19]. However, if the oxidative
stress on injured neurons can be reduced, the decreased reactive oxygen
species should allow neurons to restore their function and regulation of
their associated microvasculature. Thus, improved neuronal function
should be associated with increased cerebral blood ﬂow that can be
measured using various functional neuroimaging tools such as MRI.
The existing treatments utilized for MS focus on mitigating the immune response through methods such as dampening lymphocytic activation and inﬁltration. While these treatments are effective in
attenuating the immune response, they fall short in preventing disease
progression. Several integrative approaches for reducing psychological
stress have been shown to help reduce the development of new brain
lesions and also attenuated the accumulation of brain atrophy [20].
Similarly, lower overall stress appears to reduce future grey matter atrophy in MS patients [21]. In spite of these approaches, many MS patients
not only continue to suffer cognitive and functional debilitation through
recurrent attacks, but they are also susceptible to chronic inﬂammation
[22, 23]. It has been shown that patients on interferon-ß1 still experience
a consistent reduction in neuronal metabolic activity [24]. Finding a
therapeutic target that ameliorates oxidative stress in MS patients may
serve as a beneﬁcial adjuvant therapy.
N-acetylcysteine (NAC), an antioxidant and glutathione (GSH) precursor, is promising in this regard. NAC has been shown to increase
glutathione levels in not only hepatocytes but also in mice brains [25, 26,
27]. Additional data involving NAC and experimental autoimmune encephalitis (EAE) rodent models have shown positive results in attenuating
inﬂammatory cytokine release and oxidative stress while improving clinical signs in rats [28, 29]. NAC has also been shown to cross the blood brain
barrier to improve neuronal function through other various pathways [30].
In a previously published article on the same subjects, but with concomitantly obtained ﬂuorodeoxyglucose (FDG) positron emission tomography
(PET), we showed that there was increased cerebral glucose metabolism in
speciﬁc subregions of the temporal and frontal lobes in MS patients when
administering NAC to patients with PPMS and RRMS [31]. Thus, NAC may
present as a promising therapy for mitigating oxidative stress within patients with MS.
Magnetic resonance imaging (MRI) is used primarily to assess MS
through quantifying lesions and analyzing brain atrophy. T2-weighted
and FLAIR sequences often show enhancements signifying the presence
of demyelinating and inﬂammatory lesions [32]. MRI is also used to
monitor treatment through a combined measure of characterizing new
lesions, brain atrophy, and documenting recurrent episodes as well as
patient disability [33]. This analysis, however, does not sufﬁciently
characterize oxidative stress MS patients accrue over time. It has been
discussed that reactive oxygen species are capable of signiﬁcantly
altering cerebral blood ﬂow within the brain, which cannot be visualized
on conventional MRI methods [13]. Using magnetically labeled arterial
blood as the endogenous tracer, arterial spin labeling (ASL) perfusion
MRI, provides a completely noninvasive means to measure quantitative

2. Materials and methods
2.1. Overview of study
Written informed consent, approved by the Institutional Review
Board of Thomas Jefferson University, was obtained from all subjects and
the study was registered on clinicaltrials.gov with the following identiﬁer: NCT03032601. Subjects were recruited from local neurology ofﬁces
and also from the local community through meetings with MS support
groups in the area. To be enrolled, subjects had to meet the standard
clinical diagnosis of either relapsing remitting or progressive MS based
upon the 2010 revision to the McDonald criteria [38] along with the
following inclusion criteria: Age 21–80 years old and on stable medication regimen for at least one month. Patients were excluded if they had
any of the following: any structural intracranial abnormalities that would
prevent the analysis software from performing accurately (this does not
include the typical white matter lesions found in MS patients); and any
medical, neurological, or psychiatric disorder that could reasonably be
expected to interfere with the assessment of MS symptoms, or with any of
the study assessments including the resting ASL imaging to measure CBF
(e.g. active cardiovascular disease, liver disease, movement disorders,
stroke, active thyroid disease, major depression, bipolar disorder, and
history of acetaminophen overdose). In addition, NAC is known to
worsen asthma so a history of moderate to severe asthma was included as
part of the exclusion criteria. There are only a few medications specifically known to interfere with NAC such as charcoal, ifosfamide, and
inhaled insulin and these were excluded. In all, there were 23 MS subjects
(17 relapsing remitting and 6 primary progressive; with a mean age of
53.4  11.8 years) that qualiﬁed for the study and underwent an initial
resting ASL MRI imaging as part of a PET-MRI scan. The PET scan was
performed with FDG and this data was presented in a recently published
article [31]. Brieﬂy, FDG PET scans were obtained using standard technique before and after the NAC or waitlist condition. MIMNeuro software
was used to obtain relative glucose metabolic activity in selected regions
and comparisons were made between the pre and post intervention scans
for the NAC and control groups. Of these subjects none had symptoms of
relapse withing six months of entering the study and there were no relapses experienced during the study.
2.2. NAC intervention
Subjects were randomized using a permuted block method (using a
1:1 ratio with sealed envelopes for the allocation) either to receive
intravenous plus oral NAC or to be placed in the waitlist control condition. Subjects were not blinded so they were aware that they were in one
group or the other. A Fisher exact test was used to determine if there were
signiﬁcant baseline differences in variables such as diagnosis, medication
use, or severity of disease based on the Expanded Disability Status Scale
(EDSS). Subjects were also evaluated pre and post intervention with the
Mental Health Inventory and the Perceived Deﬁcits Questionnaire. These
questionnaires ask patients about a variety of health problems that might
be related to their MS diagnosis, for which we focused on the cognitive
function and attention/concentration subscores respectively [39, 40].
These clinical questionnaires were statistically analyzed separately using
2
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linear mixed effects (LME) models with random patient effects. The ﬁxed
effects considered include age, gender, ethnicity, treatment group, timing
(pre-therapy and post-therapy), as well as the interaction of treatment
group and timing. For two months both groups continued their current
standard of care management for MS, with the experimental group
receiving NAC in both oral and intravenous form during that same
period. NAC was obtained from the Jefferson Pharmacy as Acetadote
(Cumberland Pharmaceuticals). Pharmaceutical grade NAC is an intravenous (IV) medication most commonly used for the treatment of acetaminophen overdose. Doses of NAC were prepared for each patient by a
trained study nurse. The dose was 50 mg/kg mixed into 200ml of D5W
infused over approximately 1 h 1x per week. Subjects additionally took
500mg NAC tablets 2x per day on the days that they did not receive the IV
NAC. This was continued until presenting for the second MRI scan.

2.3.3. Whole brain CBF quantitative analysis
The mean whole brain CBF values for each subject (generated in step
5 above) at the pre and the post scan (for both the NAC group and the
control group) were calculated. The pre-scan whole brain values were
tested for normal distribution using standard kurtosis and skewness
calculation since these represented the baseline results for all MS patients. Then the difference in CBF between the post scan and the pre scan
were calculated for each subject. Using these values, the average change
in CBF in the treatment group and the control group was found and
compared using ANOVA.
2.3.4. Voxel level CBF comparison
Using SPM12 software, statistical analyses of the normalized,
smoothed, outlier corrected perfusion images were performed in order to
assess group differences in resting state cerebral blood ﬂow between the
control group and the treatment group. In order to ﬁnd the effect of NAC
treatment on CBF, the treatment and the control group were compared
using a 2  2 full factorial ANOVA design, with condition (control and
treatment) and time (pre and post) as the 2 factors utilized. The voxel
based analysis was done on the whole brain, not predeﬁned ROIs. Using a
T-contrast reﬂecting the mean difference between the two groups and the
variation within them in, the regions that survived FDR correction for
multiple comparisons with a P value < 0.001 and cluster level >10 voxels
were identiﬁed. These regions represent the change in CBF after 2
months of treatment speciﬁcally seen in the treatment group in comparison to the control group. We also explored whether there were any
regions that correlated with changes in subjective measures of cognition
and attention using linear regression analysis.

2.3. MRI acquisition, analysis, and statistics
2.3.1. MRI acquisition
Participants ﬁrst received the baseline MRI, including a highresolution structural scan. A T1 MPRAGE sequence was used to
perform this scan. The main purpose of acquiring structural image is to
better examine cortical and subcortical volumes. This was followed by a
resting state ASL scan to assess CBF in the different regions of the brain.
The scans were acquired axially using a Siemens mMR 3T PET-MRI
scanner with a 12 channel head coil. They were acquired at two time
points; Pre-intervention and Post-intervention. The T1-weighted imaging
parameters are as follows: TR ¼ 1600 ms, TE ¼ 2.46 ms, FOV ¼ 252 mm
 252mm, voxel size ¼ 0.5  0.5  1 mm3, slice thickness ¼ 1 mm, and
number of slices ¼ 176. The Echo Planar Imaging (EPI) sequence parameters used for resting state ASL (ep2d_pasl) scans are as follows: TR ¼
2500ms, TE ¼ 11ms, FOV ¼ 192 mm  192 mm, voxel size ¼ 3  3  6
mm3. An asymmetrical pulsed ASL sequence (PICORE Q2T) [41] was
utilized with the following parameters: 16 slices acquired in ascending
order, slice thickness ¼ 6 mm, Bolus Duration ¼ 1675 ms, Inversion/Delay Time ¼ 1800 ms, Labeling time ¼ 700ms and labeling pulse
ﬂip angle ¼ 90 . 119 volumes were acquired, with the 1st volume containing the M0 image and the remaining volumes containing 59 pairs of
control/labelled images.

3. Results
3.1. Clinical and demographic sample characteristics
Table 1 shows the baseline clinical characteristics for all subjects
including type of MS, use of MS medications, and EDSS score. There were
no signiﬁcant differences in these variables between the NAC and control
groups. Table 1 (see also Figure 1) also presents the global cerebral blood
ﬂow changes between the NAC and control groups. There were signiﬁcant improvements in the MHI cognition scores in the NAC group
compared to controls (NAC increased or improved by a mean of 8.611
while control group decreased by a mean of 3.056; p < 0.05) and the PDQ
attention scores (NAC decreased or improved by a mean of 1.417 while
the control group increased 0.917; p < 0.05). It should be noted that
these results have previously been reported [31].

2.3.2. MRI image processing
Preprocessing and statistical analysis was performed on all subjects
using Matlab (ver. R2018a) using the standard steps that are incorporated
as part of a validated SPM12 based ASL perfusion MRI data processing
toolbox, ASLtbx [42]. The processing steps are as follows:1) Realignment:
Rigid body spatial transformation was applied to the PASL control and
label images in order to remove motion artifacts in the PASL time-series; 2)
Co-Registration: the motion corrected PASL images and the M0 image
were co-registered to the structural T1 space; 3) Smoothing: The PASL
images were smoothed before CBF calculation to prevent noise propagation and to improve signal to noise ratio (SNR). A 6-mm full-width at half
maximum (FWHM) Gaussian kernel was used; 4) Cerebral Blood Flow
Calculation: Perfusion difference images were generated and the mean
whole brain cerebral blood ﬂow (ml/100 g/min) was calculated for each
subject by pairwise control-label subtraction using the established one
compartment model utilized by the ASLtoolbox [34, 43]; 5) Segmentation:
the anatomical images were divided into individual tissue types (grey
matter, white matter and CSF) for use in the outlier cleaning step. The
high-resolution structural image (T1-MPRAGE) were used and compared
to prior established tissue probability maps generated in SPM; 6) Outlier
cleaning: Slice wise outlier cleaning was applied to the perfusion difference
images produced in step 4 and utilized the segmentations produced in step
5 [44]; 7) Normalization: deformations produced from the SPM12 segmentation implemented in step 5 were applied to the outlier cleaned CBF
maps to transform the functional data into the standard Montreal Neurological Image (MNI) space [45].

3.2. CBF analysis results
The CBF analysis of the brain demonstrated signiﬁcant differences
between the pre and post scans for the NAC versus the control group,
however, there were no signiﬁcant differences in the baseline or pre
treatment scans between the two groups. Further, the pre-treatment
whole brain scan data met criteria for uniformly distributed data with
a kurtosis of -0.38 and skewness of 0.27. The NAC group had a mean
whole brain increase in CBF of 8.8  11.5 ml/100 g/min while the
waitlist control group had a mean whole brain decrease in CBF of 5.8 
13.5 ml/100 g/min. ANOVA analysis revealed that these are signiﬁcant
changes both within group for the NAC intervention (within group
comparison was signiﬁcant with a p ¼ 0.01) and when the NAC group
was compared to the control group (across group comparison was signiﬁcant with a p ¼ 0.006).
Exploring individual regions, we found the following areas (see
Table 2) were signiﬁcantly increased (threshold set at p ¼ 0.001) in the
NAC group post treatment compared to the controls. The voxel-wise results
are based on analysis of the whole brain, not predeﬁned ROIs and the
regions that survived FDR correction for multiple comparisons after the
whole brain voxel based analysis are presented in Table 2. Speciﬁcally,
3
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Table 1. Demographic information regarding subject number, diagnosis, medication use and EDSS score. In addition, the pre and post intervention whole brain mean
CBF is provided along with the difference.
Subject
(Dx)

Treatment
Group

MS
Medications

EDSS

Pre Group Whole Brain Mean
CBF ml/100 g/min

Post Group Whole Brain Mean
CBF ml/100 g/min

Difference in CBF ml/100 g/min
(Post treatment - Pre treatment)

MS001(RR)

NAC

None

3.0

36.19

48.78

12.59

MS002(RR)

NAC

None

4.0

62.25

64.86

2.61

MS003(RR)

NAC

Dalfampridine, Dimethyl
fumarate

3.5

77.44

92.82

15.38

MS004(RR)

NAC

Interferon beta-1a

3.0

18.04

49.11

31.07

MS005(P)

NAC

Fingolimod

2.0

23.82

35.74

11.92

MS006(RR)

NAC

Interferon beta-1a

3.0

34.36

48.70

14.34

MS007(P)

NAC

Ocrelizumab

3.5

62.63

59.91

-2.72

MS008(RR)

NAC

teriﬂunomide

3.5

46.54

52.72

6.18

MS009(RR)

NAC

teriﬂunomide

4.0

33.53

47.03

13.50

MS010(RR)

NAC

Fingolimod

2.5

76.31

82.48

6.17

MS011(RR)

NAC

Interferon beta-1a

2.0

56.06

42.16

-13.90

MS001(P)

Control

None

4.5

59.04

37.09

-21.95

MS002(RR)

Control

Dalfampridine

5.0

75.81

55.60

-20.21

MS003(RR)

Control

None

2.0

38.18

30.21

-7.97

MS004(P)

Control

Dalfampridine Ocrelizumab

4.0

25.12

48.65

23.53

MS005(RR)

Control

Dalfampridine, Dimethyl
fumarate

4.0

65.27

56.19

-9.08

MS006(RR)

Control

interferon beta-1a

3.0

83.03

90.98

7.95

MS007(P)

Control

Dimethyl fumarate

3.5

59.96

55.86

-4.10

MS008(P)

Control

Dalfampridine

2.0

85.69

73.89

-11.80

MS009(RR)

Control

Ocrelizumab

6.0

51.08

52.51

1.43

MS010(RR)

Control

teriﬂunomide

3.0

83.35

71.66

-11.69

MS011(RR)

Control

Natalizumab

2.0

110.54

89.17

-21.37

MS012(RR)

Control

Fingolimod

2.0

42.38

47.59

5.21

the neurons under duress from the MS pathophysiology might be able to
recover function and subsequently blood ﬂow to the affected regions.
While the present study found changes in CBF based on ASL data, we
cannot infer in a strict sense that the observed longitudinal perfusion
changes reﬂect alterations/reductions in oxidative stress (especially
given that a single ROI also showed a decrease of perfusion across time).
A reduction in oxidative stress is one of several possible mechanisms
underlying this observation and other possibilities include the ability of
NAC to inhibit other inﬂammatory markers or to stimulate neuronal
differentiation and neuritogenesis [52]. NAC might also have a direct
effect on the vasculature leading to altered CBF (although there are no
clear reports of such an effect in the literature). In a previous study we
conducted, we were able to observe an increase in cerebral glucose
metabolism in certain regions of the brain [31]. NAC presents itself as a
promising therapeutic in regards to reducing oxidative damage in the
brain. Moreover, it is available both as an oral supplement and as an
intravenous agent. While NAC is readily available, there is still conﬂicting evidence in regard to NAC administration and elevation of glutathione levels in the brain. Further, it is unclear whether these changes in
glutathione lead to substantial changes in cerebral blood ﬂow and clinical scores. Studies investigating oral NAC absorption alone was not only
variable but also low at (6–10%) [53, 54]. Some exercise studies have
shown oral NAC to be effective in enhancing serum glutathione levels
[48, 55]. Further, a MRS study using high doses of oral NAC (600 mg) did
not ﬁnd signiﬁcant increases in glutathione in the brain [56]. Conversely,
intravenous NAC administration increased brain glutathione levels [57].
Therefore, we decided to use a combination of both oral and intravenous
administration in an effort to accommodate the logistical difﬁculties in
receiving an injection multiple times a week while also addressing the
low bioavailability of oral NAC. In previous studies involving a NAC
intervention with Parkinson's and MS patients, we were able to observe
physiological changes in the brain suggesting that this combination is
sufﬁcient in elevating and maintaining NAC levels in the brain [31, 58].

there were signiﬁcant increases in the pons, midbrain, left superior temporal lobe, left hippocampus/parahippocampus, left frontal lobe, left
thalamus, and right temporal lobe/hippocampus. There was also signiﬁcantly reduced blood ﬂow in the right middle frontal gyrus. In comparison,
our previously reported FDG PET data showed signiﬁcant increases in
metabolism in the caudate, inferior frontal gyrus, lateral temporal gyrus,
and middle temporal gyrus [31]. No correlations were found between the
changes in cerebral blood ﬂow and subjective measures of cognition or
attention even though these were signiﬁcantly improved in the NAC group.
4. Discussion
An important facet of the pathophysiology of MS revolves around
the induction of oxidative stress. It has been shown that oxidative stress
in MS leads to numerous deﬁcits such as damage to the brain endothelium, blood brain barrier, and dysfunction of mitochondria [46].
Other studies have also provided complementary data through
observing an increase in oxidative stress markers in MS patients [23,
47]. Glutathione, an endogenous reducing agent, serves as antioxidant
that aids in protecting neurons against oxidative damage. Additional
data suggest that Glutathione levels are reduced in CNS of MS patients
[8, 48, 49]. Similar reductions were also found in the periphery [50].
This reduction in glutathione along with its inherent limited supply
within the brain predisposes MS patients to signiﬁcant oxidative stress
[51]. The accumulation of oxidative damage eventually overwhelms
the brain's inherent cellular antioxidant mechanisms leading to
dysfunctional and cell death. Although current therapies for MS are
effective disease modiﬁcation, interventions addressing the chronic
oxidative damage may be effective in improving global brain function
and alleviating neurological symptoms.
While numerous studies have investigated the effects of NAC in EAE
rodents, we investigated the effects of NAC in human patient CBF. We
hypothesized that by reducing oxidative stress with NAC administration,
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Figure 1. Panel A (top row) shows the comparison of the pre (left) and post (right) scan of an MS patient in the NAC group demonstrating a marked increase in global
CBF after two months of receiving NAC. Panel B (bottom row) shows the comparison of the pre (left) and post (right) scan of a control patient revealing a decrease in
global CBF during the waitlist period.

as the right temporal/hippocampal region. There was decreased perfusion to the right middle frontal gyrus. This highlights the notion that NAC
does not have a uniform effect on the brain but appears to target speciﬁc
regions that are affected in MS. It is possible that some reductions might
be beneﬁcial if they result from increased inhibition that is required to
maintain appropriate neuronal balance within the brain, especially with
regard to motor activity [59].
To our knowledge, this is the ﬁrst research study that has speciﬁcally
evaluated the effect of NAC in patients with MS using resting CBF data. In a
review study done by Tahedl et al. [60] the group investigated therapeutic
intervention outcome on MS patients. Although most of these works used
task-based CBF, they support the ability of such an approach as reliable
method to monitor the improvement of the disease. In another study by
Cader et al. [61], the study's aim was assessing the effect of administrating

Our current study utilized the same combination of oral and IV NAC
intervention in treating patients with relapse-remitting or primary progressive MS. Consequently, the results suggest signiﬁcant changes in
cerebral blood ﬂow to a variety of brain regions. First, there was a global
increase in mean CBF in the NAC intervention group in contrast to a
global decrease in the control group. It is not completely clear the basis
for the decrease in global CBF in the control group. It could represent
some degree of acclimatization to the study procedures reducing anxiety
during the imaging procedure, or it might represent some progressive
neuronal dysfunction as the result of the disease process. Future studies
could help conﬁrm such a ﬁnding and attempt to determine its cause.
Interestingly, certain brain regions experienced an increase while
others experienced a decrease. There were increases in CBF in the left
superior temporal lobe, hippocampus, thalamus, and frontal lobe, as well

Table 2. Comparison of brain region differences in the NAC group compared to the control group between the pre and post scan. All regions represent signiﬁcant
differences between the NAC and control group with a p < 0.001 FDR corrected and a peak T-value.
Structure

Peak MNI Coordinate

Peak Intensity (T-Value)

Cluster Size (voxels)

Pons

0 -32 -30

3.67

11

Midbrain

14 -16 -12

3.82

26

L Superior Temporal Lobe

-36 0 16

4.24

16

L Hippocampus/Parahippocampus

-24 -38 -2

3.67

13

L Frontal Lobe

-38 -4 20

4.01

10

L Thalamus

-24 -22 8

4.53

56

R Middle Frontal Gyrus

42 56 8

-5.38

53

R Temporal/Hippocampus

36 -42 2

3.56

13
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we opted for a waitlist control. Thus, it is possible then that the ﬁndings
might be attributable to placebo effects although any physiological
changes observed are expected to more likely reﬂect speciﬁc effects of the
NAC, but future studies comparing NAC to a placebo injection in a
blinded manner could elucidate any potential disparities. It would also be
pertinent to collect a measurement of either NAC or glutathione as it is
still unclear whether our intervention protocol elicits an increase of
either molecule in the brain. We could acquire these objective measures
through either a direct collection of CSF or through MR spectroscopy.
Furthermore, it would be worthwhile to observe an extended study of
NAC administration to observe any signiﬁcant changes namely in clinical
functionality and disease progression. Additional indirect measures
could also include markers of oxidative stress to help provide further
evidence to support the role of NAC in protecting neurons against
oxidative damage. In regards to the changes seen in cognition and
attention, we relied on self-reported questionnaires instead of objective
neuropsychological measures. There is substantial evidence to suggest
that self-reported and individual perception of cognition and attention
can be affected by a myriad of factors such as stress, depression, sleep,
and fatigue [68, 69, 70, 71]. We were able to observe slight improvements in these categories for patients, however, no results were statistically signiﬁcant. It is our aim to use more objective measures of cognitive
function such as speciﬁc neuropsychological testing in future studies
with a larger number of subjects to further evaluate NAC's speciﬁc effects
in the realm of patient neuropsychology.

rivastigmine and domperidone as cholinesterase inhibitors on cognitive
function of 15 MS patients using Stroop task and an N-back task. Task
based CBF analysis of the N-back task in patients who took rivastigmine
showed increase connectivity in the brain regions associated with cognition (i.e. prefrontal cortex). Patient group who took both medications,
showed enhanced execution of Stroop task which was also associated with
increased task based CBF in the prefrontal and parietal areas.
Importantly, areas of the brain with altered CBF observed in the
current study, such as parts of the frontal and temporal lobe, also had
increased metabolic activity. Thus, there appears to be an association
between changes in CBF and cerebral glucose metabolism. This could be
an important ﬁnding regarding the effect of NAC on brain processes as
well as suggesting that future research consider combined imaging as a
way of better understanding the effects of other therapeutic interventions
in MS patients. It is also important to note that since areas such as the
temporal and frontal lobe support cognitive processing and attention, the
ﬁndings of increased CBF and increased glucose metabolism indicate a
mechanism by which NAC might support these cognitive processes which
we reported previously [31]. However, we were not able to detect signiﬁcant correlations between regional changes in CBF and subjective
measures of cognition or attention due both to the small sample size, the
variability of measures, and the problem of multiple comparisons.
Additional analyses in a larger sample size that more directly compare
CBF and cerebral glucose metabolism might be beneﬁcial for better
determining this relationship.
This ﬁnding also supports the overall hypothesis that NAC may affect
CBF in neurons initially under oxidative stress resulting in improved
function and improvement in symptoms. This is also a potentially
important ﬁnding since impaired cognition is a signiﬁcant problem
among patients with MS with between 40-70% of patients affected [19,
62]. Memory, information processing speed, and attention and executive
function are cognitive domains that are most common in MS patients
[63]. Cognitive impairment also has a signiﬁcant effect on the quality of
life of MS patients [64]. The pathophysiology of cognitive impairment in
MS patients is multifactorial and includes effects of the disease itself,
medications, mood problems, fatigue, and other factors. Neuroimaging
correlates of cognitive impairment in MS patients include the degree of
white matter lesions characteristic of MS, brain atrophy, and even abnormalities in otherwise normal appearing brain tissue [65]. There has
been only limited studies evaluating resting CBF in relation to cognitive
impairment in MS patients probing the correlation of cognition and
resting state CBF in MS cohort, Cruz-Gumez [66] and the team, reported
decreased CBF in default mode network, frontoparietal (both left and
right) and salience regions of the brain. These regions were reported as
the result of analysis in cognitively impaired patients. Another study by
Louapre et al. [67] revealed that CBF was increased in attention related
networks in cognitively preserved MS patients compared to control
group. Whereas decreased connectivity in the default mode network and
attentional networks was observed comparing cognitively impaired and
preserved group. Thus, the ﬁndings from the current study are consistent
with the above-mentioned studies and suggest that NAC might alter CBF
in areas of the brain, such as the frontal and temporal lobes, that support
improvements in cognitive function.
Although we observed signiﬁcant changes in CBF in MS patients
receiving NAC, there are several important limitations to our study. The
study's sample size is small as we were limited by the costs of imaging and
weekly NAC administration. Based on the mean and standard deviation
for the whole brain CBF values, as well as the observed effect size, we
would anticipate requiring at least 30 subjects per intervention group for
future studies. In spite of this small sample, we were able to observe
signiﬁcant changes in CBF associated with NAC administration. It is
noteworthy that while we included a control group, we did not perform a
blinded study through giving control MS patients an IV placebo. Thus, it
is plausible that the changes seen in CBF could be resultant, in part, due
to a placebo effect. We opted against a blinded study as there were signiﬁcant ethical concerns raised in giving MS patients IV placebo, and thus

5. Conclusion
The overall results of the present study reveal signiﬁcantly increased
whole brain CBF in MS patients after receiving two months of NAC
compared to controls. Further, speciﬁc regions such as the midbrain,
pons, and parts of the temporal and frontal lobe also had signiﬁcant increases in CBF in the NAC group. Future, larger scale studies will be
needed in order to determine if the ﬁndings in this initial study are
corroborated and also correlated with improvements in speciﬁc symptoms and clinical markers.
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